Page 49 - 2021_10-Haematologica-web

Targeting PKC and BET induces differentiation of AML
35. Yu ZY, Xiao H, Wang LM, et al. Natural product vibsanin A induces differentiation of myeloid leukemia cells through PKC acti- vation. Cancer Res. 2016;76(9):2698-2709.
36. Kharbanda S, Saleem A, Emoto Y, Stone R, Rapp U, Kufe D. Activation of Raf-1 and mitogen-activated protein kinases during monocytic differentiation of human myeloid leukemia cells. J Biol Chem. 1994;269(2):872-878.
37. Liu CX, Zhou HC, Yin QQ, Wu YL, Chen GQ. Targeting peroxiredoxins against leukemia. Exp Cell Res. 2013;319(2):170- 176.
38.Callens C, Coulon S, Naudin J, et al. Targeting iron homeostasis induces cellular differentiation and synergizes with differen- tiating agents in acute myeloid leukemia. J Exp Med. 2010;207(4):731-750.
39. Paubelle E, Zylbersztejn F, Alkhaeir S, et al. Deferasirox and vitamin D improves overall survival in elderly patients with acute myeloid leukemia after demethylating agents failure. PLoS One. 2013;8(6):e65998.
40. Shlush LI, Zandi S, Mitchell A, et al. Identification of pre-leukaemic haematopoi- etic stem cells in acute leukaemia. Nature. 2014;506(7488):328-333.
41. Behrens K, Maul K, Tekin N, et al. RUNX1 cooperates with FLT3-ITD to induce leukemia. J Exp Med. 2017;214(3):737-752.
42.Mizuki M, Schwable J, Steur C, et al. Suppression of myeloid transcription factors and induction of STAT response genes by AML-specific Flt3 mutations. Blood. 2003;101(8):3164-3173.
43. Radomska HS, Alberich-Jorda M, Will B, Gonzalez D, Delwel R, Tenen DG. Targeting CDK1 promotes FLT3-activated acute myeloid leukemia differentiation through C/EBPalpha. J Clin Invest. 2012;122 (8):2955-2966.
44. Italiani P, Boraschi D. From monocytes to M1/M2 macrophages: phenotypical vs. functional differentiation. Front Immunol. 2014;5:514.
45. Hristodorov D, Mladenov R, von Felbert V, et al. Targeting CD64 mediates elimination
of M1 but not M2 macrophages in vitro and in cutaneous inflammation in mice and patient biopsies. MAbs. 2015;7(5):853-862.
46. O'Neill LA, Hardie DG. Metabolism of inflammation limited by AMPK and pseudo- starvation. Nature. 2013;493(7432):346-355.
47. Wang R, Dillon CP, Shi LZ, et al. The tran- scription factor Myc controls metabolic reprogramming upon T lymphocyte activa- tion. Immunity. 2011;35(6):871-882.
48. Shi J, Vakoc CR. The mechanisms behind the therapeutic activity of BET bromodomain inhibition. Mol Cell. 2014;54(5):728-736.
49. Diaz T, Rodriguez V, Lozano E, et al. The BET bromodomain inhibitor CPI203 improves lenalidomide and dexamethasone activity in in vitro and in vivo models of multiple myeloma by blockade of Ikaros and MYC signaling. Haematologica. 2017;102(10): 1776-1784.
50. Abraham SA, Hopcroft LE, Carrick E, et al. Dual targeting of p53 and c-MYC selectively eliminates leukaemic stem cells. Nature. 2016;534(7607):341-346.
haematologica | 2021; 106(10)
2577